DABIGZA 110 MG

Dabigza 110 mg is an anticoagulant medication that serves to thin the blood, thereby aiding in the prevention and management of blood clots. This medication is particularly beneficial in mitigating the risk of stroke and heart attacks. Dabigza 110 is effective in preventing clot formation in various parts of the body, including the veins located in the legs, lungs, brain, and heart. It is frequently prescribed to patients who suffer from atrial fibrillation, a type of irregular heartbeat, as it helps to avert the development of clots associated with this condition. Additionally, Dabigza 110 is utilized in individuals who have undergone knee or hip replacement surgeries to lower the likelihood of clot formation. The medication can be ingested either with or without food; however, it is advisable to take it consistently at the same time each day to maintain its effectiveness. Long-term use may be necessary, and patients should not discontinue or modify the dosage without medical consultation, as this could elevate the risk of serious complications such as heart attacks or strokes. Lifestyle modifications, including a balanced diet, regular physical activity, maintaining a healthy weight, and avoiding smoking, can further diminish the risk of developing blood clots. Common adverse reactions associated with Dabigza 110 include gastrointestinal disturbances and an increased tendency to bleed. Any unusual symptoms should be reported to a healthcare professional promptly. It is important to note that certain contraindications exist, such as severe renal or hepatic impairment, currently active bleeding, or the concurrent use of other anticoagulants.